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Aim. Investigate the promoter methylation of the Thrombospondin-1 (TSP1) gene in gastric cardia adenocarcinoma (GCA).
Methods. MSP approach, immunohistochemistry method, and RT-PCR were used respectively to examine the promoter
methylation of TSP1, its protein and mRNA expression in tumors and corresponding normal tissues. The expression and
concentration of TGF-β1 were examined respectively by immunohistochemistry and ELISA method. The status of T cell
immunity was examined by Flow cytometry analysis. Results. TSP1 was methylated in 34/96 (35.4%) tumor specimens, which was
signiﬁcantly higher than that in corresponding normal tissues (P<. 001). Protein and mRNA expression of TSP1 in GCA tumor
tissues were reduced signiﬁcantly and were associated with TSP1 methylation. The protein expression of TGF-β1 was signiﬁcantly
higher in tumor tissues (P<. 001) and was associated with TNM stage and histological diﬀerentiation. The concentration of
active and total TGF-β1 did not show signiﬁcant diﬀerence between the GCA patients with hypermethylation of TSP1 and
without methylation of TSP1 (P>. 05). The function of T cell immunity was signiﬁcantly diﬀerent between the GCA patients
with hypermethylation of TSP1 and without methylation of TSP1. Conclusions. Epigenetic silencing of TSP1 gene by promoter
hypermethylation may play an important role in GCA.
1.Introduction
Thrombospondin-1 (TSP1) is part of a thrombospondin
family which consists of ﬁve members. TSP1 and TSP2 are
parts of the ﬁrst subgroup and are trimers; TSP3, TSP4, and
TSP5 are pentamers. All thrombospondins display a high
degree of homology, but they are diﬀerentially expressed
in various tissues in order to agree with their distinct
promoters, suggesting diﬀerent functions for each member
of the thrombospondin family. TSP1 was ﬁrst described in
1971 as a high-molecular weight glycoprotein secreted from
blood platelets upon thrombin activation [1]. TSP1 is also
synthesized and secreted by various types of cells including
osteoblasts, ﬁbroblasts, monocytes, macrophages, smooth
muscle cells, and a variety of neoplastic cells [2–4]. TSP1
is a multifunctional, matricellular glycoprotein, containing
interacting domains for a large variety of adhesive proteins,
cell receptors, and enzymes, and it is involved in numerous
biological processes, including cell adhesion, migration and
proliferation, cell-cell interactions, angiogenesis, tumor cell
metastasis, inﬂammation, atherosclerosis, hemostasis, and
thrombosis [5, 6].
TSP1 inﬂuences cell behavior by interacting with other
extracellular matrix components, including latent TGF-β1,
and with speciﬁc cell surface receptors. TSP1 receptors
include αvβ3,α4β1,α5β1, and α3β1 integrins; CD36; CD47;
low-density lipoprotein receptor-related protein; and hep-
aran sulfate proteoglycans (HSPGs) [7]. TSP1 activates
latent transforming growth factor-β (TGF-β) and protects it
against inactivation through a2-macroglobulin and decorin2 Journal of Biomedicine and Biotechnology
proteoglycan [8]. The activation of TGF-β1 is one of the
primary mechanisms for regulating the activity of the TGF-β
signaling pathway. Several TSP1 receptors are expressed
in hematopoietic cells and have been implicated in the
regulation of immune functions by TSP1. Endogenous TSP1
connects separate cell-surface receptors functionally and
regulates T cell adhesion [9]. Prolonged inﬂammation in
CD47-, or TSP1-deﬁcient mice is accompanied by a local
deﬁciency of T cell apoptosis [10]. Based on global analysis
of gene expression in T cells exposed to TSP1, however, a
primary eﬀect of TSP1 is to inhibit T cell antigen receptor
(TCR) signaling [11]. TSP1 is predominantly a negative
regulator of DC and T cell function while basal SIRP-
alpha ligation on APC by CD47 enforces tolerance [12].
In contrast, stimulatory eﬀects of TSP1 or CD47-binding
peptides derived from TSP1 have also been reported for
the activation, inﬁltration, and clonal expansion of T cells
[13]. These data indicated that TSP1 can both stimulate
and inhibit speciﬁc signal transduction pathways in T cells
and these opposing responses may arise from interactions of
TSP1 with two diﬀerent T cell receptors, α4β1 and CD47 [7].
The role of TSP1 in cancer progression remains contro-
versial and presents both stimulatory and inhibitory eﬀects
[14]. Inhibition of tumor growth by TSP1 is generally
attributed to its antiangiogenic activity and several studies
have indicated that TSP1 is an inhibitor of angiogenesis
[15]. Transition from a resting to a sprouting phenotype and
mitogenic activity of cultured endothelial cells was inhibited
by TSP1 [16]. Production of TSP1 by breast carcinoma
cells can exert an inhibitory eﬀect on tumor progression
[17]. Expression of TSP1 inversely correlated with malignant
progression in melanoma, lung, and breast carcinoma cell
lines [18]. Furthermore, TSP1 may play an important role in
antitumor immunity by enhancing recruitment and activa-
tion of M1 tumor-associated macrophages, which provides
an additional selective pressure for loss of TSP1 expression
during tumor progression [19]. However, conﬂicting results
have been obtained [20], and the eﬀects of TSP1 appeared
to be speciﬁc both for the types of tumor examined and
the experimental model used [15]. The exposition of cryptic
sites upon conformational changes can partially explain this
contradiction and the analysis of TSP1-directed intracellular
signaling pathways activated through speciﬁc receptors or
supramolecular receptors docking systems may be useful
to discriminate the precise function of TSP1 in tumor
progression[14].Theseinteractionsarecomplex,andthenet
eﬀect of TSP1 to enhance or inhibit tumor progression will
need to be deﬁned for each tumor type.
It is now increasingly recognized that aberrant hyper-
methylation of the CpG island is associated with silencing
of tumor-associated genes in various tumors. Promoter
hypermethylation of the TSP1 gene has been found in some
primary human carcinomas including gastric carcinomas
and colorectal cancer [21, 22]. Methylation status of the
CpG island in promoter regions is animportant determinant
of gene expression. Gastric cardia adenocarcinoma (GCA),
which was formerly registered as esophageal cancer or
gastric cancer, has been diagnosed independently in very
recent years, due to the improvement in early endoscopic
screening and pathologic diagnosis. China is a country
with high incidence regions of GCA, especially in Taihang
mountain of North China. Exogenous factors including
nutrition deﬁciency, unhealthy living habits, consumption of
alcohol and tobacco, and pathogenic infections are generally
considered as the risk factors for developing GCA in China
[23]; however, only a subset of individuals exposed to the
above listed exogenous risk factors would develop GCA,
suggesting that multiple genetic and epigenetic events may
contribute to the occurrence and progression of GCA. To
our best knowledge, the methylation status of TSP1 and
its eﬀect on TGF-β1 in GCA still remain unknown. In
the present study, we evaluated the role of methylation of
the 5  CpG island of TSP1 and its correlation with TSP1
expression both at mRNA and protein levels in Chinese GCA
patients; moreover, to determine whether the methylation
status of TSP1 can inﬂuence the activation of TGF-β1a n d
T cell immunity, we compared the concentration of TGF-β1
and T cell immunity in GCA patients with or without
hypermethylation of TSP1.
2. Methods
2.1. Study Subjects. The cases with GCA were all inpatients
for surgical treatment in the Fourth Aﬃliated Hospital,
Hebei Medical University between 2004 and 2007. The
patients included 73 males and 23 females, mean age 57.8
years (ranged from 38 to 78 years). Two ml of venous blood
from each subject was drawn in Vacutainer tubes containing
EDTA and at the same time two ml of nenous blood from
each subject was drown in tubes without EDTA before the
operation. GCA tissues and corresponding adjacent normal
tissues were all obtained from operations. These tissues were
divided into two parallel parts, one part was frozen and
stored at −80◦C until RNA was extracted, the other part was
formalin-ﬁxed and paraﬃn-embedded. Histological tumor
typing was carried out on the basis of resected specimens
in the Department of Pathology of the same hospital.
Sample sections were stained in H&E and were examined by
two experienced pathologists. All gastric cardia carcinomas
were adenocarcinomas with their epicenters at the gastroe-
sophagealjunction,thatis,from1cmaboveuntil2cmbelow
the junction between the end of the tubular esophagus and
the beginning of the saccular stomach [24]. Information on
tumor-node-metastasis (TNM) classiﬁcation was available
from hospital recordings and pathological diagnosis, 7 of
them were stage I (7.3%), 35 were stage II (36.5%), 39 were
stage III (40.6%), and 15 were stage IV (15.6%). According
to the pathological phases, the cases were classiﬁed into
3 groups, 43 (44.8%) of them were well diﬀerentiated, 35
(36.4%) were moderate diﬀerentiated, and 18 (18.8%) were
poor diﬀerentiated. Venous blood samples with and without
EDTA from 30 healthy volunteers during the same period
were collected as the controls. The study was approved by the
Ethics Committee of Hebei Cancer Institute and informed
consent was obtained from all recruited subjects.
2.2. Methylation Analysis of TSP1. Genomic DNA from
gastric cardia adenocarcinomas and adjacent nonmalignantJournal of Biomedicine and Biotechnology 3
sections were isolated by manual microdissected method
from paraﬃn-embedded tissue slides using a simpliﬁed
proteinase K digestion method. To examine the DNA methy-
lation patterns, we treated genomic DNA with sodium bisul-
ﬁte, as described previously [25]. In brief, 2μgo fD N Aw e r e
denatured with 2M NaOH at 37◦Cf o r1 0m i n u t e s ,f o l l o w e d
by incubation with 3M sodium bisulphite (pH5.0). The
samples were over layered with mineral oil to cover surface
of the aqueous phase, and incubated at 50◦C for 16 hours.
The DNA samples were then desalted through a column of
Wizard DNA Clean-up System (Promega, Wisconsin, USA)
according to the manufacturer’s instructions. The samples
were incubated with 3M NaOH at room temperature for
ﬁve minutes, precipitated with 10M ammonium acetate and
100% ethanol, washed with 70% ethanol, and resuspended
in 20μl of distilled water.
The methylation status of TSP1 was then determined
by methylation-speciﬁc polymerase chain reaction (MSP).
Bisulfate treatment of genomic DNA converts cytosine to
uracil bases but has no eﬀect on methylcytosine. The speciﬁc
PCR was then used to distinguish between methylated and
unmethylated DNA sequences. The primer sequences for
the methylated form were 5 -TGC GAG CGT TTT TTT
AAA TGC-3  (sense) and 5 -TAA ACT CGC AAA CCA
ACT CG-3  (antisense) (74bp), and the primer sequences
for the unmethylated form were 5 - GTT TGG TTG TTG
TTT ATT GGT TG-3  (sense) and 5 -CCT AAA CTC
ACA AAC CAA CTC A-3  (antisense) (115bp). The PCR
condition consisted of one incubation of 10 minutes at
95◦C, followed by 35 cycles of 94◦C for 30s, 62◦Cf o r
30s, and 72◦Cf o r3 0 s ,a n daﬁ n a le x t e n s i o na t7 2 ◦C
for 10 minutes. PCR products were analyzed on 2%
agarose gels with ethidium bromide and visualized under
UV illumination. Genomic DNA, methylated in vitro by
CpG methyltransferase (Sss I) following the manufacturer’s
directions (New England BioLabs, Inc., Beverly, MA), was
used as a positive control. Water blank was used as a negative
control.
2.3. Immunohistochemical Staining for TSP1 and TGF-β1.
TSP1 and TGF-β1 expressions were determined by im-
munostaining method, which was performed on parallel
histopathological sections from paraﬃn-embedded tumor
section and corresponding adjacent normal tissues. Tissue
sections were deparaﬃnized in xylene, Rehydrated in graded
alcohol, and then washed in water. Endogenous peroxidase
activity was blocked with H2O2 treatment. Antigen retrieval
was achieved by incubation in 10mM boiling sodium citrate
buﬀer for 15 min and nonspeciﬁc binding was blocked
by treating the sections with 1.5% horse normal serum
for 10 minutes. The slides were sequentially incubated
with primary monoclonal anti-TSP1 (A6.1, dilution 1:50,
Abcam) and anti-TGF-β1 (sc-146, dilution 1:50, Santa
Cruz) antibodies at 4◦C overnight. The Vectastain ABC Kit
was used to obtain the ﬁnal stain. 3,3 -Diaminobenzidine
(Sigma, St Louis, MO) was used as the chromagen. The
slides were counterstained with hematoxylin. For a negative
control, the primary antibody was replaced with mouse IgG.
Slides with normal gastric mucosa were used as a positive
control.
2.4. RT-PCR Analysis of the TSP1 Transcript. RNA was
extracted from frozen section tissues by standard methods
using Trizol (Invitrogen, USA). cDNA was synthesized using
the advantage RT-for-PCR kit (Clontech, Palo Alto, CA)
with oligo (dT) priming as recommended in the protocol
provided. The GAPDH gene was used as internal control.
The primers for TSP1 were 5 -AAA GCG TCT TCA CCA
GAG ACC T-3  (sense) and 5 -GCA GAT GGT AAC TGA
GTT CTG ACA-3  (antisense) (496bp). The primers for
GAPDHwere5 -CCATGGAGAAGGCTGGGG-3  (sense),
and 5 -CAA AGT TGT CAT GGA TGA CC-3  (antisense)
(250bp). The thermal cycles were 94◦C for 5 min, followed
by 35 cycles of 94◦C for 60s, 55◦C for 60s and 72◦Cf o r
60s, and ﬁnally 72◦C for 10 minutes for extension. The PCR
products were separated in 2% agarose gel in electrophoresis
and visualized with ethidium bromide staining.
2.5. TGF-β1 ELISA Assay. The blood serum were collected
from the venous blood without EDTA of GCA patients and
healthycontrols.TheconcentrationofTGF-β1wasmeasured
with the TGF-β1 quantikine enzyme linked immunosorbent
assay (ELISA) (DB-100, R&D Systems, Minneapolis, MN)
following the manufacturer’s protocol. To measure the
concentration of active and latent TGF-β1, the serum was
divided. The ﬁrst portion of the serum was activated with
hydrochloric acid and the remaining portion of the same
media was assessed without any hydrochloric acid treatment.
The ELISA assay results were measured using a VERSAmax
microplate spectrophotometer (Molecular Devices, Sunny-
vale, CA) set at 450nm.
2.6. Flow Cytometry Analysis. Peripheral blood mononu-
clear cells (PBMC) were isolated by Ficoll-Paque (Sigma-
Aldrich) density-gradient centrifugation from venous blood
containing EDTA of GCA patients and healthy controls. A
ﬂow cytometer (Epics-XLII; Beckman Coulter) was used to
determine the cell surface expression of CD3, CD4, CD8,
CD4+-CD25+-Foxp3+- regulatory T (Treg) cells. Mononu-
clear cells were stained using monoclonal antibodies to
CD3, CD4, CD8, CD25 (BD Biosciences, San Jose, CA,
USA) and appropriate IgG isotype controls. Costaining of
intracellular FOXP3 was performed applying anti-FOXP3
monoclonal antibody PCH101 (eBioscience, San Diego,
CA, USA). Samples were analyzed using an FACSCalibur
cytometer and CELLQuest software (BD Biosciences).
2.7. Statistical Analysis. Statistical analysis was performed
using SPSS11.5 software (SPSS Company, Chicago, Illinois,
USA). Results of cell surface molecule and expression, and
the level of TGF-β1 were expressed as means ± SD. Chi-
square test, Fisher’s exact and t-tests were used according to
the data to assess statistical signiﬁcance of diﬀerences and
compare categorical associations. Two-sided tests were used
to determine signiﬁcance, and P values less than .05 were
regarded as statistically signiﬁcant for all statistic tests.4 Journal of Biomedicine and Biotechnology
Table 1: Methylation status, immunohistochemical staining characteristics of TSP1, and immunohistochemical staining characteristics of
TGF-β1i nG C Ap a t i e n t s
Methylation Protein Protein
Group status of TSP1 P expression of TSP1 P expression of TGF-β1 P
MU − + − +
TNM stage
I1 6 0 75 2
II 9 26 7 28 20 15
I I I 1 6 2 3 1 42 5 1 72 2
IV 8 7 .036a 69 .028a 41 1 .045a
Pathological
diﬀerentiation of
tumor
Well 13 30 10 33 29 14
Moderate 13 22 10 25 14 21
Poor 8 10 .551b 71 1 .463b 31 5 .001b
aP value of stage III and IV patients against stage I and II patients, bP value among three diﬀerentiation groups.
M
mu mu mumumumu
NT NTNT
Case 1 Case 2 Case 3
Figure 1: Methylation analysis of TSP1 in tumor tissue (T) and
corresponding normal tissue (N). u: indicates the presence of
unmethylated genes; m: indicates the presence of methylated genes;
M: 100bp DNA marker. Case 1: the tumor is fully methylated,
whereas the corresponding normal tissue has a very faint band
demonstrating methylation; Case2: tumor-speciﬁc methylation;
Case3: both of tumor and corresponding normal tissues are
unmethylated.
3. Results
3.1. Methylation Analysis of TSP1 in GCA. The methy-
lation analyses were successfully performed in all tumor
and corresponding normal tissues (Figure 1). For 10% of
samples, methylation analyses were repeated for quality
control. 34 (35.4%) of 96 GCA tumors displayed TSP1
methylation, while only 3 (3.1%) of paired normal tissues
were detected TSP1 methylation. Methylation frequency of
TSP1 in tumor tissues was signiﬁcantly higher than that in
paired normal tissues (P<. 001). When stratiﬁed for TNM,
stages frequencies of TSP1 methylation of GCA patients with
III and IV stages were signiﬁcantly higher than GCA patients
w i t hIa n dI Is t a g e s( χ2 = 4.40,P = .04). No signiﬁcant
association between TSP1 hypermethylation and histological
diﬀerentiation was found (χ2 = 1.19,P = .55) (Table 1).
3.2. Immunostaining of TSP1 Gene. As shown in Table 1, the
staining was heterogeneous in 27 tumor tissues (Figure 2).
Table 2: Methylation status and mRNA expression of TSP1 in GCA
patients.
TSP1 mRNA expression TSP1 methylation status
Hypermethylation Unmethylation
+6 1 7
− 22 0
χ2 = 26.134,P = .000.
Frequency of positive protein expression of TSP1 was 71.9%
(69/96) in tumor tissues, while paired normal tissues all
demonstratedpositiveexpression(P<. 001).Whenstratiﬁed
for TNM stages, Frequencies of TSP1 protein expression of
stage III and IV tumor tissues were signiﬁcantly lower than
that in stage I and II tumor tissues (χ2 = 4.85,P = .03).
TSP1 protein expression did not correlate with histological
diﬀerentiation (χ2 = 1.54,P = .46). The tumor tissues
without hypermethylation of TSP1 (62 of 96, 64.6%) all
demonstrated positive protein expression of TSP1. A close
correlation was noted between TSP1 hypermethylation and
the loss of TSP1 protein expression in GCA (P<. 001)
(Table 1).
3.3. mRNA Expression of TSP1 in GCA. TSP1 mRNA expres-
sion was examined by RT-PCR in 45 GCA samples and
correspondingnormaltissues(Figure 3).TSP1wasexpressed
in all 45 corresponding normal tissues. The TSP1 mRNA
expression levels in GCA tumor tissues were signiﬁcantly
lower than in corresponding normal tissues (OD value:
0.2254 ± 0.1925 versus 0.6964 ± 0.1815, P<. 01).
TSP1 mRNA expression of stage III and IV tumor tissues
was signiﬁcantly lower than that in stage I and II tumor
tissues (OD value: 0.1523 ± 0.0914 versus 0.2994 ± 0.1624,
P<. 01). 22/28 tumor samples with hypermethylation of
TSP1 did not show TSP1 transcripts. All of the 17 tumor
samples without hypermethylation of TSP1 showed positive
TSP1 mRNA expression. Overall, there was a signiﬁcantJournal of Biomedicine and Biotechnology 5
(a) (SP×200) (b) (SP×200)
(c) (SP×200) (d) (SP×200)
Figure 2: Protein expression of TSP1 and TGF-β1 in GCA tissues. (a) Positive staining of TSP1, (b) negative staining of TSP1, (c) positive
staining of TGF-β1, (d) negative staining of TGF-β1.
12 3456 7 (bp)
500
100
(bp)
496
250
Figure3:RT-PCRanalysisofTSP1intumortissues.1:100bpDNA
marker; 2,5,6,7: negative mRNA expression; 3,4: positive mRNA
expression.
Table 3:MethylationstatusofTSP1andproteinexpressionofTGF-
β1 in GCA patients.
TGF-β1 protein expression TSP1 methylation status
Hypermethylation Unmethylation
+2 4 2 6
− 10 36
χ2 = 7.223,P = .007.
correlation between TSP1 promoter hypermethylation and
loss of TSP1 mRNA expression in GCA samples (P<. 001)
(Table 2).
3.4. Immunostaining of TGF-β1 Gene. The frequency of
positive expression of TGF-β1 in GCA was 52.1% (50/96),
while only 14.6% (14/96) corresponding normal tissues
showed positive protein expression of TGF-β1( P<. 001)
(Figure 2). When stratiﬁed for TNM stages, frequencies
of TGF-β1 expression of stage III and IV tumor tissues
were signiﬁcantly higher than that in stage I and II tumor
tissues (χ2 = 4.03,P = .04). When stratiﬁed for histo-
logical diﬀerentiation, the expression of TGF-β1 showed
a signiﬁcant diﬀerence among the three groups (χ2 =
14.49,P = .001). 24 tumor tissues with hypermethylation of
TSP1 displayed positive protein expression of TGF-β1a n d
there was a signiﬁcant correlation between TSP1 promoter
hypermethylation and positive protein expression of TGF-β1
(P<. 01) (Table 3).
3.5. The Level of TGF-β1 in GCA. ELISA array was used
to demonstrate the level of total and activated TGF-β1
in GCA patients. We found that the total concentration
of TGF-β1 in GCA patients was signiﬁcantly higher than
that in healthy controls (17.25 ± 6.02μg/L versus 11.96 ±
3.05μg/L; P<. 05), while the concentration of activated
TGF-β1 did not show signiﬁcant diﬀerence between the
two groups (8.26 ± 5.07μg/L versus 8.89 ± 4.17μg/L; P>
.05). The concentration of total TGF-β1 in stage III and IV
tumor patients was signiﬁcantly higher than that in stage
I and II tumor patients (20.85 ± 5.36μg/L versus 13.05 ±
4.87μg/L; P<. 05). Upon providing evidence that whether
the aberrant methylation of TSP1 can aﬀect the level of total
and active TGF-β1, we further assessed the association of
TSP1 methylation and the level of TGF-β1. We found that
the total level of TGF-β1 did not show signiﬁcant diﬀerence
between the GCA patients with hypermethylation of TSP1
and the GCA patients without hypermethylation of TSP1
(17.01 ± 4.12μg/L versus 17.38 ± 5.26μg/L; P>. 05),
while the active TGF-β1 was lower in the GCA patients6 Journal of Biomedicine and Biotechnology
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Figure 4: The concentration of total and active TGF-β1i nd i ﬀerent
groups. 1: healthy controls, 2: GCA patients, 3: GCA patients with
TSP1 methylation, 4: GCA patients without TSP1 methylation, 5:
stage I and II GCA patients, 6: stage III and IV GCA patients.
with hypermethylation of TSP1 than that in the GCA
patients without hypermethylation of TSP1, but did not
show signiﬁcant diﬀerence (7.96 ± 3.18μg/L versus 8.65 ±
4.28μg/L; P>. 05) (Figure 4).
3.6. TSP1 Methylation and the Association with T Cell
Immunity. CD3+ cells (55.6 ± 8.5% versus 67.7 ± 7.5%;
P<. 05), CD4+ cells (33.9 ± 7.6% versus 45.8 ± 6.9%;
P<. 05), and CD4+/CD8+ (0.9 ± 0.2% versus 1.6 ± 0.3%;
P<. 05) were signiﬁcantly lower in GCA patients than those
in healthy controls, while CD8+ cells (38.1 ± 6.9% Versus
27.6 ± 8.1%; P<. 05), and CD4+-CD25+-Foxp3+-T r e gc e l l s
(7.1 ± 1.7% versus 5.2 ± 0.7%; P<. 05) were signiﬁcantly
higher in GCA patients than those in healthy controls. When
stratiﬁed for TNM stages, CD3+ cells (40.3 ± 6.8% versus
69.2 ± 7.7%; P<. 05), CD4+ cells (27.1 ± 7.8 % versus 41.4
± 6.9%; P<. 05), and CD4+/CD8+ (0.6 ± 0.2% versus 1.2 ±
0.3%; P<. 05) were signiﬁcantly lower and CD8+ cells (42.2
± 7.9% versus 30.7 ± 7.3%; P<. 05), CD4+-CD25+-Foxp3+-
Treg cells (8.2 ± 2.0% versus 5.9 ± 1.2%; P<. 05) were
signiﬁcantly higher in stage III and IV tumor patients than
those in stage I and II tumor patients. We also found that
CD4+ cells (28.2 ± 8.1 % versus 39.1 ± 6.9%; P<. 05), and
CD4+/CD8+ (0.8 ± 0.2% versus 1.1 ± 0.3%; P<. 05) were
signiﬁcantlylowerandCD8+ cells(40.8 ±5.9%versus31.9 ±
6.8%;P<. 05),CD4+-CD25+-Foxp3+-T r egc ells(7.9±1.5%
versus 6.2 ± 1.1%; P<. 05) were signiﬁcantly higher in GCA
patients with hypermethylation of TSP1 than those in GCA
patients without methylation of TSP1, while CD3+ cells did
not show signiﬁcant diﬀerence between the two groups (54.8
± 6.9% versus 55.9 ± 7.6%; P>. 05) (Figure 5)( Table 4).
Table 4: The level of TGF-β1 in GCA patients (μg/L)
Group
Level of total
TGF-β1 P
Level of active
TGF-β1 P
(X ± S) (X ± S)
Control 11.9 ± 3.1 8.8 ± 4.1
GCA patients 17.2 ± 6.0 .002a 8.2 ± 5.0 .253a
Stage I and II
GCA patients 13.0 ± 4.8 8.0 ± 3.2
Stage III and
IV GCA
patients
20.8 ± 5.3 .001b 8.3 ± 4.0 .356b
GCA patients
with
methylation
of TSP1
17.0 ± 4.1 7.9 ± 3.1
GCA patients
without
methylation
of TSP1
17.3 ± 5.2 .423c 8.6 ± 4.2 .106c
aP valueofGCApatientsversuscontrol, bP valueofstageIIIandIVpatients
versus I and II patients, cP value of GCA patients without methylation of
TSP versus GCA patients with methylation of TSP1.
4. Discussion
China is a country with high incidence of digestive tract
cancer including esophageal carcinoma, gastric cancer, and
gastric cardia adenocarcinoma. GCA is highly prevalent in
North China, especially in TaiHang mountain of Hebei
province. It has been suggested by several epidemiological
data that the incidence of GCA is increasing in very recent
years [26]. The exact mechanism of the occurrence of GCA
remains unclear for the moment. Genetic abnormalities
of proto-oncogenes and tumor suppressor genes are well-
known changes that are frequently involved in cancer
pathogenesis; however, epigenetic inactivation of certain
tumor suppressor genes by aberrant promoter methylation is
frequently observed in several cancers and may play a pivotal
role in tumorigenesis. TSP1 is one of the genes that has been
found to be aberrantly methylated in some colorectal cancers
as well as in neuroblastomas, and gastric cancers. It has been
suggested that methylated TSP1 may promote tumorigenesis
through its eﬀects on angiogenesis [27–29]. In the present
study, we found hypermethylation of TSP1 in 35.4% GCA
tumors and its reduced expression at mRNA and protein
levels in GCA tumors. In addition, there was a signiﬁcant
concordance between promoter methylation of TSP1 and its
lack of protein expression, which indicated that epigenetic
silencing of the TSP1 promoter via hypermethylation may be
one of the critical mechanism for inactivation of this gene in
GCA.
Inourstudy,wefoundthatinthemajorityofthecaseswe
examined, TSP1 methylation was tumor speciﬁc; however,
there were 3 cases (3.1%) in which the methylation change
was present in both tumor and paired normal tissues from
the same patient. Given the high sensitivity of MSP analysis,Journal of Biomedicine and Biotechnology 7
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Figure 5: T cell immunity of diﬀerent groups. (a) CD3, CD4, and CD8 cells in diﬀerent groups, (b) CD3/CD8 in diﬀerent groups, (c):
CD4+-CD25+-Foxp3+-Treg cells in diﬀerent groups, 1: healthy controls, 2: GCA patients, 3: GCA patients with TSP1 methylation, 4: GCA
patients without TSP1 methylation, 5: stage I and II GCA patients, 6: stage III and IV GCA patients.
it is possible that normal-appearing specimens contained a
rare cancer cell that was undetectable by histomorphology;
furthermore, the presence of the hypermethylation in cor-
responding noncancerous tissues may represent the appear-
ance of premalignant lesions. The fact that we only detected
methylation in paired normal tissues from patients in whom
the corresponding tumor was also methylated is consistent
with the hypothesis that the cancer in these individuals arose
from a methylated clonal precursor. In a study of neoplastic
progression in Barrett’s esophagus, hypermethylation of the
tumor suppressor gene p16 was detected in pathologically
normal-appearing specimens obtained from a patient who
later developed dysplasia [30]. Therefore, epigenetic inacti-
vation of tumor-associated genes may be an aberrant and
early feature of tumorigenesis.
To our best knowledge, no study of TSP1 promoter
methylation and protein expression in GCA has been
reported. Recently, there were studies about the correlation
of promoter hypermethylation of TSP1 with gastric cancer
and colorectal cancer [21, 22]; however, the frequency of
TSP1 methylation in these tumors and the correlation
of TSP1 methylation with histological diﬀerentiation and8 Journal of Biomedicine and Biotechnology
tumour staging were diﬀerent. Oue et al. found promoter
hypermethylation of the TSP1 gene in 10 (33%) of 30 gastric
carcinomas and it was associated with mRNA expression
levels; however, there was no correlation between TSP1
mRNA expression levels and T grade, N grade, tumor stage,
or histological type [21]. Rojas et al. detected hyperme-
t h y l a t i o no fT S P 1i n2 1 %c o l o na d e n o c a r c i n o m a s[ 22].
Here, we demonstrated that TSP1 hypermethylation was
correlated with tumor stage in patients with GCA. Types
of tumors were diﬀerent among these studies may be one
of the reasons; diﬀerent proportion of patients according to
TNM classiﬁcation and diﬀerentiation of tumors may also
lead to the above reported diﬀerence. Our results showed
that protein expression of TSP1 in tumor tissues was sig-
niﬁcantly lower than that in paired normal tissues; however,
immunohistochemical staining also showed positive staining
of TSP1 in some tumor samples with TSP1 methylation.
Gene heterogenic methylation or partial methylation may
be an important reason. Several studies have reported that
partial methylation could cause gene expression in the
tumor cells despite promoter hypermethylation [31]. In
our studies, we found that the tumor tissues both showed
hypermethylation and positive protein expression were all
incomplete TSP1 methylation. Furthermore, it has been
demonstrated that DNA methylation which suppressed gene
expression mainly in transcriptional level and the density
of CpG island methylation was related to the suppressed
degree of transcription [32]. In our study, we also found
positive mRNA expression in some tumor samples with
TSP1 methylation. It is partly due to the fact that the extent
of promoter methylation was insuﬃcient to suppress TSP1
transcription.
TGF-β is a pluripotent cytokine that has a multitude
of eﬀects on epithelial cells including the inhibition of
proliferation, the duction of apoptosis, and the stimulation
of diﬀerentiation. It has been demonstrated that TSP1 is
required for the activation of secreted TGF-β1, and the
activation of TGF-β1 is one of the primary mechanisms for
regulating the activity of the TGF-β signaling pathway. Once
TGF-β1 is activated, it can bind to and activate the TGF-β
receptor, inducing postreceptor signaling pathways [22]. In
this study, we demonstrated that the protein expression of
TGF-β1 was signiﬁcantly higher in tumor tissues and was
associated with TNM stage and histological diﬀerentiation.
The total level of TGF-β1 was higher in GCA patients and
was associated with TNM stage. TGF-β1 has the eﬀect of
inhibiting the proliferation of human B and T cells and is
prevalently viewed as an immune suppressive cytokine. The
higher protein expression of TGF-β1 in GCA patients was
consistent with its function. Rojas et al. found that TSP1
inactivation inhibits the activation of secreted TGF-β1, and
aberrant methylation of TSP1 can suppress TGF-β signaling
by impairing the activation of TGF-β1[ 22]; however, in
our study we did not ﬁnd statistical diﬀerence of active
TGF-β1 level between GCA patients with TSP1 methylation
and without TSP1 methylation. This diﬀerence probably due
to the fact that our investigation was in vivo while Rojas’s
was in vitro and as a signaling pathway, TGF-β1a c t i v a t i o n
byTSP1cannotbeconsideredastheessentialwaytogenerate
active TGF-β1 in GCA and the activation of TGF-β1m a yb e
inﬂuenced not only by TSP1 but by other genes as well. It
has been found that proteases such as plasmin and matrix
metalloproteinases,reactiveoxygenspecies,andtheintegrins
αvβ6o rαvβ8 can also have the eﬀect of activating TGF-β1
[33, 34].
Thedeﬁningfeatureofafunctionalimmunesystemisthe
ability to correctly discern foreign pathogenic antigens from
self- or other innocuous antigens and to mount an eﬀective
immune response. T lymphocytes are the key components
of the cellular arm of the adaptive immune system. In view
of the association of TSP1 and TGF-β1, we further evaluated
the function of T cell immunity in GCA patients. We found
that CD3, CD4 cells and CD4/CD8 were lower and CD8
were higher in GCA patients and were associated with TNM
stage. Foxp3-expressing Treg cells, playing critical roles in
suppressing the immune response, were also found higher
in GCA patients. We have provided the evidence that GCA
patients have the decreased T cell immunity and with the
development of the cancer it has become more serious. We
also showed similar tendency between GCA patients with
TSP1 methylation and GCA patients without TSP1 methy-
lation. TGF-β and Foxp3-expressing Treg cells are critical in
maintaining self-tolerance and immune homeostasis. TGF-
β1 suppresses immune responses through at least two ways:
inhibiting the function of inﬂammatory cells and promoting
the function of Treg cells. TGF-β1 is expressed in Treg at
high levels as a cell-surface-bound form [35]. It has been
found that TSP1 can promote the generation of human
peripheral Treg cells through CD47. CD47 stimulation by
mAb or a TSP1 peptide induced naive or memory CD4+
CD25− T cells to become suppressive. The latter expressed
increased amounts of CTLA-4, OX40, GITR, and Foxp3
and inhibited autologous Th0, Th1, and Th2 cells [36].
In our study, Treg cells were higher in GCA patients with
hypermethylated TSP1, it partly due to the fact that the
proportionofstageIIIandIVGCApatients(54of96,56.3%)
was higher than stage I and II tumor patients (42 of 96,
43.7%); Treg cells and the frequency of TSP1 methylation of
stage III and IV GCA patients were also higher than those
of stage I and II tumor patients. The stage III and GCA
patients in our study both showed lower T cell immunity
function and higher frequency of TSP1 methylation. Further
work should be done in a larger cases to detect the exact
mechanism.
In summary, Our results suggested that the aberrant
methylation of TSP1 is an epigenetic event that silences
this gene in gastric cardia adenocarcinoma, and TSP1 may
not be the main factor of activating TGF-β1 in this cancer.
Further work is necessary to elucidate its exact function
and interaction with other factors to develop strategies for
early diagnosis, prevention, and treatment of gastric cardia
adenocarcinoma.
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